Clinical Trial

Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
It is a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 clinical trial to evaluate the efficacy of QLM3003 ointment at week 8 based on the primary endpoint (EASI 75) and key secondary endpoint (IGA-TS).in patients with mild to moderate atopic dermatitis. A total of 360 patients with mild to moderate atopic dermatitis are planned to be included and randomized at a ratio of 1:1:1 to receive 1.5% QLM3003 ointment、2% QLM3003 ointment and placebo, twice a day.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-11; most recent amendment 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2025-08-19
Trial Details
NCT Number NCT06880276
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Atopic Dermatitis
Enrollment 360 participants
Start Date 2025-05-16
Primary Completion 2027-03 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2025-08-26